Novartis AG Common Stock (NVS)

About NVS

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthri…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

75,267

Website

www.novartis.com/

Fundamentals

1-day range

$152.77$154.57

Market cap

$293.23B

P/E (trailing)

21.95

P/E (forward)

15.68

EPS (trailing)

$6.62

Dividend yield

3.72%

Beta

1.16

Avg. volume

1.87M

Ex-dividend date

March 11, 2026

Dividend pay date

March 16, 2026

Forecasts

11 analyst ratings

Novartis AG Common Stock Competitors

Chosen by industry and closest market cap.

• NVS

  Novartis AG Common Stock

  $153.79

  ▼ 0.56%
  Market cap $293.23BP/E 21.95
  $96.03$131.5
• MRK

  Merck & Company Inc. Common Stock (new)

  $148.32

  ▼ 0.82%
  Market cap $315.57BP/E 103.86
  $77.58$156.92
• AZN

  AstraZeneca PLC Ordinary Shares

  $162.69

  ▼ 1.11%
  Market cap $244.97BP/E 23.44
  $10,784$15,730
• NVO

  Novo Nordisk A/S Common Stock

  $45.6

  ▼ 1.43%
  Market cap $208.51BP/E 11.40
  $224.25$409.95
• ABT

  Abbott Laboratories Common Stock

  $112.42

  ▲ 0.74%
  Market cap $185.36BP/E 35.52
  $81.97$137.49
• ABBV

  AbbVie Inc. Common Stock

  $255.56

  ▼ 1.01%
  Market cap $433.04BP/E 70.24
  $190.75$267.47
• PFE

  Pfizer Inc. Common Stock

  $27.95

  ▼ 0.25%
  Market cap $142.66BP/E 35.19
  $23.58$28.75

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
  SeekingAlpha · 8/26/2026
• Regeneron: Why I Still See Upside After The Rally
  SeekingAlpha · 8/25/2026
• TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
  SeekingAlpha · 8/22/2026
• Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors
  ChartMill · 8/21/2026
• Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
  benzinga · 8/18/2026
• Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
  Benzinga · 8/18/2026
• Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
  SeekingAlpha · 8/13/2026
• Roche Is Getting More Benefit Of The Doubt On Improving Execution
  SeekingAlpha · 8/13/2026
• 10 Health Care Stocks With Whale Alerts In Today’s Session
  Benzinga · 8/12/2026

Institutional Ownership

March 31, 2026

Total shares held

147.23M

Total value held

$21.60B

Institutional holders

1572